Deutsche Bank Ag\ Trevi Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$287 Billion
Q3 2025

A detailed history of Deutsche Bank Ag\ transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 51,640 shares of TRVI stock, worth $585,081. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,640

Previous 43,437 18.88%

Holding current value

$585,081

Previous $237,000 94.51%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$5.62 - $9.62 $46,100 - $78,912	8,203 Added 18.88%	51,640 $461,000
Q2 2025 Aug 12, 2025	BUY	$5.28 - $7.06 $30,682 - $41,025	5,811 Added 15.44%	43,437 $237,000
Q1 2025 May 09, 2025	BUY	$3.66 - $6.81 $30,681 - $57,088	8,383 Added 28.67%	37,626 $236,000
Q4 2024 Jun 30, 2025	SELL	$2.53 - $4.5 $21,208 - $37,723	-8,383 Reduced 22.28%	29,243 $124,000
Q4 2024 Feb 14, 2025	BUY	$2.53 - $4.5 $1,733 - $3,082	685 Added 2.4%	29,243 $124,000

Q3 2024 Jun 26, 2025	SELL	$2.58 - $3.51 $23,395 - $31,828	-9,068 Reduced 24.1%	28,558 $95,000
Q3 2024 Nov 13, 2024	BUY	$2.58 - $3.51 $37,758 - $51,368	14,635 Added 105.11%	28,558 $95,000
Q2 2024 Jun 12, 2025	SELL	$2.44 - $3.36 $57,835 - $79,642	-23,703 Reduced 63.0%	13,923 $41,000
Q2 2024 Aug 14, 2024	SELL	$2.44 - $3.36 $9,501 - $13,083	-3,894 Reduced 21.86%	13,923 $41,000
Q1 2024 Jun 02, 2025	SELL	$1.3 - $3.7 $25,751 - $73,293	-19,809 Reduced 52.65%	17,817 $61,000
Q1 2024 May 15, 2024	BUY	$1.3 - $3.7 $23,162 - $65,922	17,817 New	17,817 $61,000
Q3 2023 Nov 09, 2023	BUY	$2.11 - $2.47 $52,897 - $61,922	25,070 New	25,070 $54,000

Others Institutions Holding TRVI

# of Institutions

174

Shares Held

119M

Call Options Held

629K

Put Options Held

1.22M

View Full List

About Trevi Therapeutics, Inc.

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $661M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

More about TRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account